RETRACTED ARTICLE: Superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer

Fu, Lilan; Huang, Shun; Wu, Hubing; Dong, Yun; Xie, Fei; Wu, Ruihe; Zhou, Kemin; Tang, Ganghua; Zhou, Wenlan

doi:10.1007/s00330-022-08743-1

Cited by 33 publications

(42 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FAPI PET/CT is a new functional imaging technique. Many studies have shown that, compared with 18 F-FDG PET/CT, 68 Ga-FAPI PET/CT and 18 F-FAPI PET/CT have better imaging sensitivity for various tumors [25,26]. A recent study indicated that 68 Ga-FAPI PET/CT was better at identifying liver lesions than 18 F-FDG PET/CT [27].…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of 18F-FAPI PET/CT in assessing early-stage fibrosis of liver after liver transplantation: preliminary experience

Fang

Xie

Zhao

et al. 2022

Preprint

View full text Add to dashboard Cite

Aims: To investigate the clinical usefulness and performance of 18F-FAPI PET/CT in assessing early-stage liver fibrosis in liver transplantation (LT) recipients.Methods: A prospective study including 17 LT recipients and 12 chronic Hepatitis B (CHB) patients was performed. All patients received liver biopsy, transient elastography (TE), and 18F-FAPI PET/CT. The maximum standardized uptake values (SUVmax) of the liver parenchyma were recorded on 18F-FAPI PET/CT images. The receiver operating characteristic (ROC) curve analysis was applied to determine the diagnostic efficacy of 18F-FAPI PET/CT in early-stage liver fibrosis (S1 ~ S2) compared with the diagnostic performance of TE.Results: Of 29 patients, 15(51.7%) had fibrosis stage 0 (S0), 10(34.5%) had stage 1 (S1), and 4(13.8%) had stage 2 (S2) respectively. The SUVmax of patients with early-stage liver fibrosis were significantly higher than those without liver fibrosis in LT recipients and CHB patients (p=0.004, p=0.02). In LT recipients, a SUVmax cut-off value of 2.0 detected early-stage liver fibrosis with an AUROC of 0.92 (P=0.006) and a Liver Stiffness measurements (LSM) score cut-off value of 8.2 kPa detected early-stage liver fibrosis with an AUROC of 0.80 (P=0.012). In CHB patients, a SUVmax cut-off value of 2.7 detected early-stage liver fibrosis with an AUROC of 0.94 (P<0.001) and a LSM scores cut-off value of 8.4 kPa detected early-stage liver fibrosis with an AUROC of 0.91 (P<0.001).Conclusions: 18F-FAPI PET/CT could be applied to evaluate early-stage liver fibrosis in LT recipients and CHB patients accurately. Compared with TE, 18F-FAPI PET/CT was comparable in detecting early-stage liver fibrosis with the additional advantages in whole-liver evaluation.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Value of 18F-FAPI PET/CT in assessing early-stage fibrosis of liver after liver transplantation: preliminary experience

Fang

Xie

Zhao

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…It is characterized by a strong desmoplastic response, and the association between FAP overexpression and a poor cancer prognosis has led to development of FAP-speci c inhibitors (FAPIs) [21]. In recent years, FAPIs labeled with 67 Ga-or 18 F and detected by PET have been used to provide information on tumor diagnosis and radiotherapy planning [34,35]. However, this technique (which is referred to as tumor stromal imaging) is intended to detect pathological conditions associated with tumors and does not directly depict the tumor cells themselves.…”

Section: Discussionmentioning

confidence: 99%

Exploration of the threshold SUV for diagnosis of malignancy using 18F-FBPA PET/CT

Isohashi

Kanai

Aihara

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The goal of the study was to evaluate the diagnostic ability of 18F-FBPA PET/CT for malignant tumors. Findings from 18F-FBPA and 18F-FDG PET/CT were compared with pathological diagnoses in patients with malignant tumors or benign lesions. Methods A total of 82 patients (45 males, 37 females; median age, 63 years; age range, 20–89 years) with various types of malignant tumors or benign lesions such as inflammation and granulomas were examined by 18F-FDG and 18F-FBPA PET/CT. Tumor uptake of FDG or FBPA was quantified using the maximum standardized uptake value (SUVmax). The final diagnosis was confirmed by cytopathology or histopathological findings of the specimen after biopsy or surgery. A ROC curve was constructed from the SUVmax values of each PET image, and the area under the curve (AUC) and cutoff values were calculated. Results The SUVmax for 18F-FDG PET/CT did not differ significantly for malignant tumors and benign lesions (10.9 ± 6.3 vs. 9.1 ± 2.7 P = 0.62), whereas SUVmax for 18F-FBPA PET/CT was significantly higher for malignant tumors (5.1 ± 3.0 vs. 2.9 ± 0.6, P < 0.001). The best SUVmax cutoffs for distinguishing malignant tumors from benign lesions were 11.16 for 18F-FDG PET/CT (sensitivity 0.909, specificity 0.390) and 3.24 for 18F-FBPA PET/CT (sensitivity 0.818, specificity 0.753). ROC analysis showed significantly different AUC values for 18F-FDG and 18F-FBPA PET/CT (0.547 vs. 0.834, p < 0.001). Conclusion 18F-FBPA PET/CT showed superior diagnostic ability over 18F-FDG PET/CT in differential diagnosis of malignant tumors and benign lesions. The results of this study suggest that 18F-FBPA PET/CT diagnosis may reduce the need for invasive biopsy and surgery to determine the benign or malignant nature of a lesion.

show abstract

“…Interestingly, we also analyzed whether additional blood tests for abnormally increased gastrointestinal tumor markers (CEA, CA199, CA125) could correct the false-positive 68 Ga-FAPI-04 PET results as non-recurrence. The results indicated that, although 16.7% (3/18) cases were corrected, it caused 61.1% (11/18) of the nonrecurrent cases to be misjudged as recurrence (Table 2).…”

Section: B)mentioning

confidence: 99%

“…Recently, fibroblast activation protein (FAP) targeted 68 Ga-FAPI-04 PET/CT imaging has shown overwhelming superiority compared with ¹⁸F-FDG PET/CT imaging in diagnosing primary tumors, lymph node metastasis, and peritoneal carcinomatosis in gastrointestinal cancer patients [9][10][11][12][13][14][15][16][17][18]. Based on previous studies, we hypothesized that 68 Ga-FAPI-04 PET imaging might be superior in detecting anastomotic recurrence compared to ¹⁸F-FDG PET imaging, since low FAP expression on macrophages, which are the primary inflammatory cells avid to ¹⁸F-FDG [19].…”

Section: Introductionmentioning

confidence: 99%

68Ga-FAPI-04 PET for surveillance of anastomotic recurrence in postoperative patients with gastrointestinal cancer: a comparative study with 18F-FDG PET

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: 68Ga-FAPI-04 PET imaging has shown clinical advantages for detecting and staging various solid tumor types, including gastrointestinal cancer. This study aims to compare the diagnostic efficacy of 68Ga-FAPI-04 PET and 18F-FDG PET for detecting anastomotic recurrence in postoperative patients with gastrointestinal cancer and to characterize the pattern of 68Ga-FAPI-04 uptake at surgical wounds post-surgery. Methods: This study involved 63 gastrointestinal cancer patients who underwent 68Ga-FAPI-04 and 18F-FDG PET/CT imaging, or 68Ga-FAPI-04 PET/CT imaging only for postoperative surveillance after curative surgical resection. The SUVmax at surgical wounds (anastomotic sites and abdominal incision sites) and its corresponding ratio compared to background were assessed. Endoscopic pathology confirmed anastomotic recurrence or it was ruled out by imaging and clinical follow-up. The sensitivity, specificity, positive and negative predictive values (PPV and NPV), and accuracy of the two PET imaging in detecting anastomotic recurrence were compared based on the analysis of paired FAPI-FDG PET imaging. Relationships between tracer uptake at surgical wounds and postoperative time were also analyzed. Results: Sensitivity, specificity, PPV, NPV, and accuracy of detecting anastomotic recurrence were 100.0%, 87.3%, 41.7%, 100.0%, and 88.3% for 68Ga-FAPI-04 PET imaging, and 60.0%, 81.8%, 23.1%, 95.7%, and 80.0% for 18F-FDG PET imaging respectively. Compared with non-recurrent patients, the recurrent patients exhibited a significantly higher anastomotic SUVmax and ratio on FAPI-PET imaging (SUVmax : 9.92±4.36 vs. 2.81±1.86, P =0.002; Ratio: 5.11±1.99 vs. 2.23±1.17, P <0.001). 68Ga-FAPI-04 PET displayed a significantly higher SUVmax ratio at surgical wounds than 18F-FDG PET imaging (anastomotic sites: 2.57±1.61 vs. 1.76±0.74, P =0.001; abdominal incision sites: 2.14±1.47 vs. 1.65±1.12, P =0.029). Although 68Ga-FAPI-04 PET signal at surgical wounds showed a slight trend to decrease over time (anastomotic SUVmax : r=-0.2830, P =0.0223; incisional SUVmax : r=-0.4549, P <0.0001), no statistical difference was observed over months post-surgery ( P >0.05). Conclusion: The surveillance power of 68Ga-FAPI-04 PET is superior to 18F-FDG PET in postoperative anastomotic recurrence of gastrointestinal cancer, but the positive predictive value was limited due to wound healing inference. Therefore, combined surveillance methods were suggested instead of relying on 68Ga-FAPI-04 or 18F-FDG PET only.

show abstract

RETRACTED ARTICLE: Superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer

Cited by 33 publications

References 31 publications

Clinical Value of 18F-FAPI PET/CT in assessing early-stage fibrosis of liver after liver transplantation: preliminary experience

Clinical Value of 18F-FAPI PET/CT in assessing early-stage fibrosis of liver after liver transplantation: preliminary experience

Exploration of the threshold SUV for diagnosis of malignancy using 18F-FBPA PET/CT

68Ga-FAPI-04 PET for surveillance of anastomotic recurrence in postoperative patients with gastrointestinal cancer: a comparative study with 18F-FDG PET

Contact Info

Product

Resources

About